Neurology

Galcanezumab Effective at Decreasing Monthly Headache Days in Migraine



Approximately 40% of patients with episodic migraine who were treated with galcanezumab achieved 100% response rate for at least 1 month.

Source link

Related posts

Stroke risk factors in couples. A population-based study in community-dwelling adults living in a remote rural setting (the Atahualpa Project)

Newsemia

How To Self-Care While On A ‘Deserted Island’

Newsemia

What's happening in Neurology(R) Genetics

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World